© Reuters. FILE PHOTO: The logo of AstraZeneca is seen on medication packages in a pharmacy in London
(Reuters) – Shares of AstraZeneca (NASDAQ:) fell 8% early on Monday, hit by doubts about the British firm’s strategy and speculation of a rival bid after it announced the $39 billion purchase of Alexion Pharmaceuticals (NASDAQ:) over the weekend.
Chief Executive Officer Pascal Soriot had told reporters on Saturday that the deal, a bet on rare-disease and immunology drugs, was the result of exclusive talks and no competitive bidder was involved.
The move also helps AstraZeneca, which is also working on a COVID-19 vaccine, diversify from its fast-growing cancer business.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.